Lynparza (Olaparib) for ovarian cancer maintenance treatment added tothe latest PBS list.


Australian women will now have affordable access to Lynparza (Olaparib) for ovarian cancer maintenance treatment after the drug was included in the latest PBS list.

Treasurer Josh Frydenberg’s budget speech on Tuesday announced that from November 1 2020, Olaparib, a drug that costs more than $140,000 per course, will be available for about $41 a month for general patients and $6.60 for concession cardholders. Olaparib has already been approved in treatment use for ovarian patients with a germline BRCA mutation, but this latest announcement includes financial support for patients receiving maintenance treatment.

The Australian government’s investment in new PBS medicines continues to grow, with more than 2,450 new or amended medicines listed on the PBS through an investment of more than $11.8 billion since 2013.